| Literature DB >> 21349713 |
Xingang Fang1, Yen Ting Chen, E Hampton Sessions, Sarwat Chowdhury, Tomas Vojkovsky, Yan Yin, Jennifer R Pocas, Wayne Grant, Thomas Schröter, Li Lin, Claudia Ruiz, Michael D Cameron, Philip LoGrasso, Thomas D Bannister, Yangbo Feng.
Abstract
Rho kinase (ROCK) is an attractive therapeutic target for various diseases including glaucoma, hypertension, and spinal cord injury. Herein, we report the development of a series of ROCK-II inhibitors based on 4-quinazolinone and quinazoline scaffolds. SAR studies at three positions of the quinazoline core led to the identification of analogs with high potency against ROCK-II and good selectivity over protein kinase A (PKA).Entities:
Mesh：
Substances：
Year: 2011 PMID： 21349713 DOI： 10.1016/j.bmcl.2011.01.039
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823